ArticleJCI insight2016

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.

Katherine A Minson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.